ELIZABETH BAILEY: Open Payments
NPI 1215004809 · PORTLAND, ME. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,519 in 40 payments from 13 companies in 2025. Trend: 2023 $2,484 · 2024 $17,194 · 2025 $1,519
Food & beverage: $888Consulting: $550Travel & lodging: $68Education: $12
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $572 |
| ABBVIE INC. | 10 | $252 |
| Madrigal Pharmaceuticals | 8 | $236 |
| Boston Scientific Corporation | 2 | $115 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $74 |
| Janssen Biotech, Inc. | 2 | $49 |
| Lilly USA, LLC | 2 | $42 |
| Regeneron Healthcare Solutions, Inc. | 2 | $41 |
| Gilead Sciences, Inc. | 2 | $33 |
| Novo Nordisk Inc | 2 | $33 |
Products named: XIFAXAN, REZDIFFRA, General - Therapies, ENTYVIO, LINZESS, DUPIXENT, RINVOQ, TREMFYA.
Industry payments across ME — which companies pay providers there.
